Last reviewed · How we verify
Apixaban MR2
Factor Xa inhibitor
Factor Xa inhibitor Used for Prevention of stroke and systemic embolism in non-valvular atrial fibrillation, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.
At a glance
| Generic name | Apixaban MR2 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
Apixaban is a direct oral anticoagulant that inhibits factor Xa, a key enzyme in the coagulation cascade.
Approved indications
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
- Treatment of deep vein thrombosis
- Treatment of pulmonary embolism
Common side effects
- Major bleeding
- Gastrointestinal bleeding
- Hemorrhage
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apixaban MR2 CI brief — competitive landscape report
- Apixaban MR2 updates RSS · CI watch RSS
- Pfizer portfolio CI